Longeveron (NASDAQ:LGVN) versus Janux Therapeutics (NASDAQ:JANX) Head-To-Head Survey

Janux Therapeutics (NASDAQ:JANXGet Free Report) and Longeveron (NASDAQ:LGVNGet Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Valuation & Earnings

This table compares Janux Therapeutics and Longeveron’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Janux Therapeutics $8.61 million 53.92 -$63.06 million ($1.63) -6.18
Longeveron $1.22 million 37.65 -$18.83 million ($0.95) -2.28

Longeveron has lower revenue, but higher earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.


This table compares Janux Therapeutics and Longeveron’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Janux Therapeutics -862.89% -21.22% -18.68%
Longeveron -2,265.19% -109.93% -82.53%

Risk & Volatility

Janux Therapeutics has a beta of 1.57, indicating that its stock price is 57% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.54, indicating that its stock price is 46% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Janux Therapeutics and Longeveron, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Janux Therapeutics 0 0 3 0 3.00
Longeveron 0 0 1 0 3.00

Janux Therapeutics presently has a consensus target price of $28.33, indicating a potential upside of 181.36%. Longeveron has a consensus target price of $12.50, indicating a potential upside of 476.04%. Given Longeveron’s higher possible upside, analysts plainly believe Longeveron is more favorable than Janux Therapeutics.

Institutional and Insider Ownership

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Longeveron shares are held by institutional investors. 35.4% of Janux Therapeutics shares are held by company insiders. Comparatively, 75.2% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.


Janux Therapeutics beats Longeveron on 8 of the 12 factors compared between the two stocks.

About Janux Therapeutics

(Get Free Report)

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on proprietary Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients suffering from cancer. Its lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. The company is also developing a TRACIr costimulatory bispecific product candidate against programmed death-ligand 1 and Cluster of Differentiation 28 designed to improve the anti-tumor activity of T cells. In addition, its PSMA-TRACTr is designed to target PSMA, a protein expressed in prostate cancer tumors and the vasculature of other tumors; EGFR-TRACTr is designed to target EGFR in various cancer types with multiple approved monoclonal antibodies; and TROP2-TRACTr is designed to target TROP2, a clinically validated anti-tumor target for which there is an approved anti-TROP2 antibody-drug conjugate. The company was incorporated in 2017 and is headquartered in San Diego, California.

About Longeveron

(Get Free Report)

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, an allogeneic medicinal signaling cell therapy product isolated from the bone marrow of young, healthy adult donors. It is conducting Phase 1, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is headquartered in Miami, Florida.

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.